Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

The SELECT trial, first conducted in 2023, demonstrated that semaglutide could reduce the risk of major heart events—such as ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests. The drug, ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide ...

People taking Zepbound, lost nearly 50% more weight than those using rival Wegovy in the first head-to-head study of the ...

Wegovy and Mounjaro have been taking the world by storm for their unprecedented ability to help people shed weight. New ...

The drug, containing semaglutide, curbs appetite and is ... This suggests the drug’s protection against heart disease is not only related to its effect on driving weight loss, researchers ...